NEW YORK (GenomeWeb) – Microbiome health management firm DayTwo announced on Tuesday that it has raised $12 million in a Series A financing round.
Participants in the round include Johnson & Johnson Innovation-JJDC, Seventure Partners, the Mayo Clinic, DayTwo Cofounder Marius Nacht, and other private investors. DayTwo has raised $17 million to date.
DayTwo currently offers a personalized nutrition service that includes diet recommendations, provided via a mobile app, that are based on DNA sequencing of a customer's gut bacteria from a stool sample.
The company said that it intends to use the funding to expand its product, engineering, and data science teams in Tel Aviv, Israel and San Francisco. DayTwo said the money will also support research with the Mayo Clinic and other gut microbiome clinical research partners.
"Having the financial support and domain expertise of JJDC, Seventure, Cofounder Marius Nacht, and our Israeli private equity investor group will enable us to execute our vision even more rapidly and broadly — with consumers, practitioners, health centers, and medical device partners," DayTwo CEO Lihi Segal said in a statement.